Eagle Pharmaceuticals Inc (NAS:EGRX)
$ 3.54 -0.27 (-7.09%) Market Cap: 45.87 Mil Enterprise Value: 105.50 Mil PE Ratio: 3.89 PB Ratio: 0.18 GF Score: 62/100

Eagle Pharmaceuticals Inc Corporate Call To Discuss BARHEMSYS®, BYFAVO® and Landiolol Opportunities Transcript

Mar 31, 2022 / 12:30PM GMT
Release Date Price: $49.49 (-0.02%)
Operator

Good day, everyone. My name is Ashley, and I will be your conference operator. At this time, I'd like to welcome everyone to the Eagle Pharmaceuticals Product Update and Opportunities Call. (Operator Instructions) As a reminder, this conference call is being recorded today, March 31, 2022.

It is now my pleasure to turn today's call over to Ms. Lisa Wilson, Investor Relations for Eagle Pharmaceuticals. Please go ahead.

Lisa Wilson;In;Site Communications;President
Inc.

Thank you, operator. Good morning, and thank you for joining today's presentation. This is Lisa Wilson, Investor Relations for Eagle Pharmaceuticals. With me on today's call are Eagle's President and Chief Executive Officer, Scott Tarriff; Chief Financial Officer, Brian Cahill; Chief Commercial Officer, Mike Moran; and Dr. Mike Greenberg, Vice President, Medical Affairs. A webcast of this call can be accessed through the Investors section of the Eagle website at eagleus.com. The archived webcast will be available for 1 year on our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot